- Using genetic variants to evaluate the causal effect of cholesterol
- 2 lowering on head and neck cancer risk: a Mendelian randomization
- 3 study
- 4 Mark Gormley ^{1,2,3}*, James Yarmolinsky ^{1,3}, Tom Dudding ^{1,2,3}, Kimberley Burrows ^{1,3}, Richard M
- 5 Martin^{1,3,4}, Steven Thomas^{2,4}, Jessica Tyrrell⁵, Paul Brennan⁶, Miranda Pring², Stefania
- 6 Boccia^{7,8}, Andrew F Olshan⁹, Brenda Diergaarde¹⁰, Rayjean J. Hung^{11,12}, Geoffrey Liu^{12,13},
- 7 Danny Legge¹⁴, Eloiza H Tajara¹⁵, Patricia Severino ¹⁶, Martin Lacko¹⁷, Andrew R Ness⁴,
- 8 George Davey Smith^{1,3}, Emma E Vincent^{1,3,14&}, Rebecca C Richmond^{1,3&}
- 9 ¹ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
- 10 University of Bristol, Bristol, UK.
- ² Bristol Dental Hospital and School, University of Bristol, Bristol, UK.
- 12 ³ Department of Population Health Sciences, Bristol Medical School, University of Bristol,
- 13 Bristol, UK.
- ⁴ National Institute for Health Research Bristol Biomedical Research Centre at the University
- 15 Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.
- ⁵ University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.
- 17 ⁶ Genetic Epidemiology Group, World Health Organization, International Agency for
- 18 Research on Cancer, Lyon, France.

⁷ Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, 19 20 Italy. ⁸ Department of Woman and Child Health and Public Health, Public Health Area, Fondazione 21 22 Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. ⁹ Department of Epidemiology, Gillings School of Global Public Health, University of North 23 24 Carolina, US. ¹⁰ Department of Human Genetics, Graduate School of Public Health, University of 25 26 Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, US. ¹¹ Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research 27 28 Institute, Sinai Health System, Toronto, Canada. 29 ¹² Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 30 ¹³ Princess Margaret Cancer Centre, Toronto Canada. 31 ¹⁴ School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. 32 ¹⁵ School of Medicine of São José do Rio Preto, São Paulo, Brazil. 33 ¹⁶ Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São 34 35 Paulo, Brazil. ¹⁷ Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute 36 GROW, Maastricht University Medical Center, Maastricht, The Netherlands. 37

Corresponding author

* Email: mark.gormley@bristol.ac.uk

Author contributions

[&] These authors also contributed equally to this work.

E.E.V. and R.C.R. are joint senior authors. M.G., R.C.R. and E.E.V. conceived the study and M.G. carried out data curation and formal analysis. K.B. performed the GWAS of head and neck cancer in UK Biobank. Head and neck cancer summary genetic data was obtained through multiple collaborations from studies lead and curated by A.R.N., S.T., A.F.O., B.D., R.J.H., G.L., M.L., E.T., S.B. and P.B. Expert guidance on MR methodology was provided by R.C.R., J.Y., G.D.S. and R.M.M., R.C.R., G.D.S, J.T., S.T., P.B., R.M.M. and A.R.N. provided expertise on both observational and genetic epidemiological methodology and analysis. The initial manuscript was drafted by M.G., R.C.R. and E.E.V. All authors (M.G., J.Y., T.D., K.B., R.M.M., S.T., J.T., A.R.N., P.B., M.P., S.B., A.F.O., B.D., R.J.H., G.L., D.L., E.H.T., P.S., M.L., A.R.N., G.D.S., E.E.V. and R.C.R.) contributed to the interpretation of the results, editing and critical revision of the manuscript. M.G.'s PhD supervisory team includes R.C.R., E.E.V., J.T., A.R.N. and G.D.S.

Abbreviations: HNSCC, head and neck squamous cell carcinoma; OC, oral cancer; OPC, oropharyngeal cancer; HPV, human papilloma virus; MR, Mendelian randomization; GWAS, genome-wide association study; SNP, single nucleotide polymorphism; PCA, principal component analysis; NOME, no measurement error; SIMEX, simulation extrapolation; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; GAME-ON, Genetic Associations and Mechanisms in Oncology; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; NPC1L1, NPC1 like intracellular cholesterol transporter 1; CETP, cholesteryl ester transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low-density lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LD, linkage disequilibrium; OR, odds ratio; se, standard error; IVW, inverse variance weighted; CI, confidence intervals; P, p-value.

Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to reduce disease burden include discovery of novel therapies and repurposing of existing drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer risk.

Methods and findings

We conducted two-sample Mendelian randomization (MR). For the primary analysis, germline genetic variants in *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* were used to proxy the effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies on OC and OPC risk.

The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and 6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC

cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses combined in a fixed-effects meta-analysis.

We found limited evidence of a causal effect of genetically-proxied LDL-C lowering using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk. Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%Cl 1.2, 2.8, p= 9.31×10^{-05}), with good concordance between GAME-ON and UK Biobank ($I^2 = 22\%$). Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%Cl 1.4, 4.9) than OC (OR 1.4 95%Cl 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7, 95%Cl 0.5, 1.0, p= 0.006). A series of pleiotropy-robust and outlier detection methods showed that pleiotropy did not bias our findings.

Conclusion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk, suggesting previous observational results may have been confounded. There was some evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol lowering effects, but further replication of this finding is required.

Author summary

Why was this study done?

- To determine if genetically-proxied cholesterol-lowering drugs (such as statins which target HMGCR) reduce oral and oropharyngeal cancer risk.
- To determine if genetically-proxied circulating lipid traits (e.g. low-density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.

What did the researchers do and find?

- There was little evidence that genetically-proxied inhibition of HMGCR (target of statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or oropharyngeal cancer risk.
- There was little evidence of an effect of circulating lipid traits on oral or oropharyngeal cancer risk.
 - There was some evidence that genetically-proxied inhibition of PCSK9 increases,
 while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk.

What do these findings mean?

- These findings suggest that the results of previous observational studies examining the effect of statins on oral and oropharyngeal risk may have been confounded.
- Given we found little evidence of an effect of other cholesterol lowering therapies,
 the mechanism of action of PCSK9 may be independent of cholesterol-lowering.
 Further replication of this finding in other head and neck cancer datasets is required.

Introduction

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity (OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over 550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements in the treatment of HNSCC, survival ranges between 19 - 59% at 10 years [3] and recurrence rates remain high [4]. Patients often undergo a combination of surgery, radiotherapy and chemotherapy which can result in significant morbidity [5]. Established risk factors include smoking, alcohol and human papilloma virus (HPV), the latter mainly linked with oropharyngeal cancer [6, 7]. Given that in contemporary cohorts, around 70% of OPC cases (versus <5% of OC cases) are HPV driven and often present in younger populations, oral and oropharyngeal tumours are considered distinct disease entities, with different risk factor profiles [8]. Despite smoking cessation, alcohol reduction measures and the implementation of HPV vaccination in some areas, HNSCC remains a major global health problem [2]. Novel strategies for prevention of HNSCC are required, in particular for those at high risk and one approach is to identify novel risk factors which can be easily modified, for example by repurposing existing drugs [9].

Statins are one of the most commonly prescribed medications worldwide. They are prescribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-C), with proven preventative and therapeutic effects in cardiovascular disease and a good safety profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway, responsible for cholesterol and steroid hormone synthesis [12]. Other clinically approved

drugs that target cholesterol metabolism via different mechanisms include ezetimibe (targeting Niemann-Pick C1-like protein (NPC1L1)) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors such as evolocumab or alirocumab. These agents act by reducing the intestinal absorption of cholesterol or by enhancing uptake of LDL-C through increased cellular membrane expression of the LDL-receptor (LDLR), respectively. Conversely, cholesteryl ester transfer protein inhibitors (CETP) substantially increase levels of high-density lipoprotein cholesterol (HDL-C), lower levels of LDL-C and enhance reverse cholesterol transport [13].

Cholesterol is vital for a variety of key cellular functions, including membrane integrity, signalling, protein synthesis and cell cycle progression. Therefore, modulation of cholesterol synthesis has the potential to influence several hallmarks of tumourigenesis including cell migration and proliferation [14]. In an experimental study, mice given oral daily doses of simvastatin two weeks prior to subcutaneous injection of FaDu (HPV-negative hypopharyngeal tumour cells), showed a significant reduction in tumour growth. This study was designed to mimic a clinical scenario where patients who present with a tumour may have been taking the medication prior to tumour initiation [15], and suggested that simvastatin antagonises tumour metabolic reprogramming, another important hallmark of cancer [15]. Mechanistic support for the role of LDL-C lowering in cancer development comes largely from the fact that lipids are themselves major cell membrane components essential for cell division and maintaining tissue integrity. Changes in lipid levels have been reported associated with tumour development [16, 17].

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

However, the evidence that cholesterol-lowering drugs may reduce the risk of head and neck cancer is limited. Some observational studies report an inverse association of taking statins with both head and neck cancer risk and survival [14, 18], but others indicate little evidence of any effect [19]. Observational studies are not randomised and are susceptible to reverse causality and/or confounding [19]. Mendelian randomization (MR) is an approach that uses germline genetic proxies (referred to as instruments) to help appraise causal effects of potentially modifiable extrinsic exposures or intrinsic traits with disease [20-22]. It has also been used to estimate therapeutic potential by investigating genetic variation at drug targets [23]. Numerous single nucleotide polymorphisms (SNPs) are associated with lower levels of circulating LDL-C [24, 25] and inheriting an LDL-C lowering allele has been proposed to be analogous to being assigned life-long treatment with a cholesterol lowering drug [26]. In this way, germline genetic variants may serve as proxies for exposure to potential pharmacological agents which are less likely than observational measures to be subject to reverse causation or confounding. Genetic proxies can therefore be used to predict both the likely beneficial and adverse effects of long-term modulation of the drug targets on disease.

MR has previously demonstrated the protective effect of cholesterol-lowering drugs on cardiovascular disease risk [27], but also that inhibition of HMGCR and PCSK9 may have an adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have shown that genetically-proxied inhibition of HMGCR may be protective against overall cancer [29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the causal nature and mechanistic basis of the relationship between cholesterol-lowering and

risk of oral and oropharyngeal cancer by investigating germline variation in HMGCR,

NPC1L1, CETP, PCSK9 and LDLR, and other related lipid traits such as circulating LDL-C.

Methods

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

Identifying cholesterol-lowering genetic instruments. For the primary analysis, SNPs in HMGCR, NPC1L1, CETP, PCSK9 and LDLR were used to proxy the effect of lipid-lowering therapies and to estimate the downstream effect of manipulating these targets on OC and OPC risk. SNPs were identified within 100 kb on either side of the target gene (HMGCR, NPC1L1, CETP, PCSK9 and LDLR) that were associated with LDL-C levels. Variants were robustly associated with LDL-C in a meta-analysis of genome-wide association studies (GWAS) involving 188,578 individuals primarily (96%) of European ancestry in the Global Lipids Genetic Consortium (GLGC) [25]. Linkage disequilibrium (LD) (r²) was evaluated to check the overlap between variants using LDmatrix (4.0 Release) [31]. Proxy SNPs were permitted to be in weak LD ($r^2 < 0.2$) with each other, to increase the proportion of variance explained in each respective drug target therefore maximising instrument strength. Multiple papers have used these genetic instruments at this threshold, to demonstrate causal effects in cardiovascular disease [13, 27, 32], diabetes [28] and ovarian cancer [30]. In secondary analyses, SNPs were used to proxy circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A and B. Betas represented the change in lipid trait levels per copy of the effect allele. These SNPs were already independently ($r^2 < 0.001$) associated with the respective traits in large GWAS which have been described previously [25, 33].

Summary level genetic data on oral and oropharyngeal cancer from GAME-ON.

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [34]. The study population included participants from Europe (45.3%), North America (43.9%) and South America (10.8%). Cancer cases comprised the following the International Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code (other). A total of 954 individuals with cancers of hypopharynx, unknown code or overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray custom designed for cancer studies by the OncoArray Consortium [35]. In GAME-ON, all SNPs with a call rate of <95% were excluded. Given the ethnic heterogeneity of the study population, the dataset was divided by geographical region and SNPs within each region that showed deviation from Hardy-Weinberg Equilibrium (HWE) in controls (p= <1 $\times 10^{-7}$) were excluded. Principal component analysis (PCA) was performed using approximately 10,000 common markers in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139 population outliers were removed. Full details of the included studies, as well as the genotyping and imputation performed, have been described previously [34, 36].

Two-sample Mendelian randomization. Two-sample MR was conducted using the "TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for cholesterol-lowering (sample 1) with those for OC and OPC in GAME-ON (sample 2). For

those SNPs instrumenting LDL-C lowering, we first extracted summary statistics for the associations with OC and OPC from GAME-ON. We next performed harmonisation of the direction of effects between the cholesterol-lowering exposures and outcome (OC or OPC) where, for each variant, the allele designated the 'exposure allele' was associated with lower LDL-C levels and palindromic SNPs were aligned when MAFs were <0.3 or were otherwise excluded. In our primary analysis, four palindromic SNPs, one in *HMGCR* (rs2006760), the other in *PCSK9* (rs2149041) and two in *CETP* (rs5880, rs9929488) were removed. In the secondary analysis with other lipid traits, 11 palindromic SNPs (rs1936800, rs2288912, rs7112577, rs964184, rs150617279, rs1883711, rs4722043, rs2156552, rs2954029, rs581080, rs7534572) were removed.

Individual effect-estimates for each SNP were calculated using the Wald ratio, by dividing the SNP-outcome association by the SNP-exposure association. Multiple SNPs were then combined into multi-allelic instruments using the random-effects inverse-variance weighted (IVW) meta-analysis method, for each of the genes HMGCR, NPC1L1, CETP, PCSK9 and LDLR. This meta-analysis was undertaken to increase the proportion of variance in drug targets and LDL-C lowering explained by each instrument, and thus improve statistical power and the precision of our estimates [37]. The analysis produced an estimate of the effect of the risk factor on OC and OPC risk. As the instruments for HMGCR, NPC1L1, CETP, PCSK9 and LDLR were in weak LD ($r^2 < 0.2$), we accounted for this correlation between SNPs in the primary analysis using LDlink (4.0 Release) which employs Phase 3 (Version 5) of the 1000 Genomes Project and variant rs numbers based on dbSNP. Correlation matrices were inserted as an MRInput object [31], resulting in MR methods which altered the weightings for correlated SNPs [38-40]. For circulating lipid traits, a more stringent $r^2 < 0.001$ was

already applied in the initial GWAS [25], so we did not account further for correlation in the secondary analysis. We computed odds ratios (OR) which represent the change in odds of oral and oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of the drug target, equivalent to a 1 mg/dl decrease in LDL-C. The OR was scaled to be per 1 mmol/L decrease by dividing the LDL-C lowering effect (beta) and standard error (se) measured in mg/dL by 38.7 [30]. The betas and standard errors for *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* SNPs were also converted to reflect the cholesterol-lowering effect, given the "TwoSampleMR" package preference to automatically change these into a positive direction of effect (i.e. lipid increasing). The correct direction of effect was checked using a positive control of coronary heart disease from the CARDIoGRAM GWAS data [41]. MR was also used to examine the effect of circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A and B levels directly with OC and OPC cancer risk. The ORs in this analysis represent the change in odds of oral or oropharyngeal squamous cell carcinoma, per SD unit increase in lipid trait.

The IVW method can provide an unbiased effect estimate in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced [42]. We therefore performed sensitivity analyses to evaluate the potential for unbalanced horizontal pleiotropy, where genetic variants influence two or more traits through independent biological pathways. To ensure the genetic instrument was associated with the instrument it was proxying, estimates of the proportion of variance in each risk factor explained by the instrument (R^2) and F-statistics were generated. An F-statistic of <10 is indicative of a weak instrument which may be subject to weak instrument bias. To account for directional pleiotropy, we compared the IVW results with three MR sensitivity analyses, which each

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

make different assumptions: MR Egger [43], weighted median [44] and weighted mode [45]. While these three methods are best used when genetic instruments consist of a large numbers of independent SNPs, since r² values between SNPs in our instruments were low $(r^2 < 0.2)$, we a-priori decided to include them, with a further sensitivity analysis to account for correlation in the MR Egger analysis. The weighted median stipulates that at least 50% of the weight in the analysis stems from variants that are valid instruments [44], while the weighted mode requires that the largest subset of instruments which identify the same causal effect to be valid instruments [45]. MR-Egger can provide unbiased estimates even when all SNPs in an instrument violate the exclusion restriction assumption (i.e. affect the outcome by means other than via the risk factor of interest). However, there must be negligible measurement error (NOME) [46] in the genetic instrument and the InSIDE (Instrument Strength Independent of Direct Effect) assumption must be satisfied [43]. Where there was evidence of violation of the NOME assumption, this was assessed using the I² statistic and MR-Egger was performed with simulation extrapolation (SIMEX) correction [46]. To further assess the robustness of findings, we examined evidence of heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may indicate the presence of invalid instruments (e.g. due to horizontal pleiotropy) [47]. Scatter and leave-one-out plots were produced to evaluate influential outliers and MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for potential outliers (where Q-statistic p < 0.05) [48].

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

Stratification by cancer subsite. Given the difference in established aetiology (i.e. smoking, alcohol and HPV) at each HNSCC subsite [6], we performed MR analyses with stratification by cancer subsite to evaluate potential heterogeneity in effects. For this, we used GWAS summary data on a subset of 2,641 OPC cases and 2,990 OC cases from the 6,034 HNSCC cases and the 6,585 common controls in the GAME-ON GWAS [34]. Replication in UK Biobank. UK Biobank data was used as a replication dataset for primary analyses. A GWAS was performed on 839 combined OC and OPC cases and 372,016 controls, with two further stratified GWAS for OC (n= 357) and OPC (n= 494). UK Biobank is a large population-based cohort study that recruited over 500,000 men and women aged between 37 and 73 years between 2006 and 2010 throughout the UK. It received ethical approval from the National Health Service North West Centre for Research Ethics Committee (reference: 11/NW/0382). Details of genotyping quality control, phasing and imputation are described elsewhere [49]. Participant records are linked to cancer registry data and HNSCC was grouped using the same ICD-codes as described above. Squamous cell carcinoma cases were identified using histology codes 8070 - 8078. UK Biobank GWAS analyses were adjusted for sex and genotyping array and performed in BOLT-LMM, a mixed model that accounts for population stratification and relatedness [50, 51]. Primary MR analyses as described above in GAME-ON were repeated in UK Biobank data. Meta-analysis of results. We performed both fixed-effects and random-effects metaanalysis of the MR estimates in GAME-ON and UK Biobank using the R package 'meta'. However, we focus more on the fixed-effects estimates since we assume that the causal effect is constant between the studies [52]. Heterogeneity between study populations was assessed using I^2 statistic [53].

Results

Primary analysis in GAME-ON. In total, 5 SNPs in *HMGCR* (rs12916, rs17238484, rs5909, rs2303152, rs10066707) were used to proxy HMG-CoA reductase inhibition (statins); 5 SNPs in *NPC1L1* (rs217386, rs2073547, rs7791240, rs10234070, rs2300414) proxied NPC1L1 inhibition (ezetimibe); 6 SNPs in *CETP* (rs9989419, rs12708967, rs3764261, rs1800775, rs1864163, rs289714) proxied CETP inhibition; 6 SNPs in *PCSK9* (rs11206510, rs2479409, rs2479394, rs10888897, rs7552841, rs562556) proxied PCSK9 inhibition; 3 SNPs proxied cholesterol-lowering in *LDLR* (rs6511720, rs1122608, rs688) (LDL-receptor inhibition). Further details of these SNP effects are given in **Table 1**.

Table 1. Detailed summary of LDL-C lowering genetic variants in *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* variants from the in Global Lipids Genetics Consortium (GLGC)

Target	SNP	Pathway	EA	OA	EAF	Beta	se	<i>P</i> -value
HMGCR	rs12916	LDL-C	T	С	0.57	-0.06061	0.003	7.79E-78
	rs17238484	LDL-C	G	Т	0.75	-0.05184	0.005	1.35E-21
	rs5909	LDL-C	G	Α	0.90	-0.05102	0.007	4.93E-13
	rs2303152	LDL-C	G	Α	0.88	-0.03498	0.005	1.04E-09
	rs10066707	LDL-C	G	Α	0.58	-0.0411	0.005	2.97E-19
	rs2006760*	LDL-C	С	G	0.81	-0.04407	0.006	1.67E-13
NPC1L1	rs217386	LDL-C	Α	G	0.41	-0.02908	0.003	1.20E-19
	rs2073547	LDL-C	Α	G	0.81	-0.03885	0.004	1.92E-21
	rs7791240	LDL-C	Т	С	0.91	-0.03404	0.005	1.84E-10
	rs10234070	LDL-C	С	Т	0.90	-0.02363	0.005	1.52E-06

	rs2300414	LDL-C	G	Α	0.93	-0.02828	0.006	5.45E-06
CETP	rs3764261	LDL-C	Α	С	0.29	-0.04471	0.004	2.22E-34
	rs1800775	LDL-C	Α	С	0.48	-0.03487	0.003	8.54E-24
	rs1864163	LDL-C	G	Α	0.73	-0.03698	0.004	7.97E-21
	rs9929488*	LDL-C	G	С	0.70	-0.03159	0.004	8.15E-13
	rs9989419	LDL-C	G	Α	0.60	-0.02344	0.004	2.49E-12
	rs12708967	LDL-C	Т	С	0.80	-0.02963	0.004	3.47E-11
	rs289714	LDL-C	Α	G	0.79	-0.03032	0.005	2.85E-10
	rs5880*	LDL-C	G	С	0.94	-0.03979	0.008	1.59E-06
PCSK9	rs11206510	LDL-C	С	Т	0.15	-0.06871	0.001	2.38E-53
	rs2479409	LDL-C	Α	G	0.67	-0.05309	0.001	2.52E-50
	rs2149041*	LDL-C	С	G	0.84	-0.05259	0.001	1.44E-35
	rs2479394	LDL-C	Α	G	0.72	-0.03192	0.001	1.58E-19
	rs10888897	LDL-C	Т	С	0.40	-0.04192	0.001	8.43E-31
	rs7552841	LDL-C	С	Т	0.63	-0.04589	0.001	5.40E-15
	rs562556	LDL-C	G	Α	0.19	-0.05292	0.002	6.16E-21
LDLR	rs6511720	LDL-C	Т	G	0.11	-0.17482	0.004	3.69E-54
	rs1122608	LDL-C	Т	G	0.23	-0.05473	0.003	2.02E-86
	rs688	LDL-C	С	Т	0.56	-0.04465	0.003	3.04E-48

EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-effect allele; EAF, effect allele frequency; se= standard error. * Palindromic SNPs removed

Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L to mg/dL, multiply by 38.7.

There was limited evidence of an effect of genetically-proxied inhibition of HMGCR and NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p= 0.82 and 1.0; 95% CI 0.4, 2.7, p= 0.99), respectively. (Table 2 and S1 Fig). A similar result was found for genetically-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3; 95%CI 0.6, 2.6, p= 0.49) (Table 2 and S1 Fig). However, higher risk of combined OC and OPC was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p= 0.01; Table 2 and Fig 1). This is in contrast to the reduction in odds seen in relation to cardiovascular disease using the same instrument (OR IVW 0.6; 95%CI 0.4, 0.8, p <1 x10⁻⁰³; Fig 2) in 60,801 cases and 123,504

385

386

387

388

389

390

391

392

393

394

395

396

control subjects enrolled in the CARDIOGRAM consortia studies [41]. There was also some evidence that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%CI 0.4, 1.0, p = 0.05; **Table 2, Fig 1**). Fig 1. Forest plot showing the causal effects of HMGCR, NPC1L1, CETP, PCSK9 and LDLR variants on the oral and oropharyngeal cancer subsites in GAME-ON. Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale. Fig 2. Forest plots showing the causal effects of cholesterol-lowering PCSK9 and LDLR single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON. Effect estimates on oral and oropharyngeal cancer are reported the log odds scale. on

Table 2. Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON

					IVW		Weighted median		Weighted mode		MR-Egger	
	Outcome	Exposure/ Outcome dataset	Outcome N	Number of SNPs	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
		GAME-ON/ GLGC										
	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.07 (0.62, 1.84)	0.82	1.20 (0.63, 2.28)	0.58	1.20 (0.57, 2.50)	0.66	1.33 (0.07, 26.58)	0.86
HMGCR	Oral cancer	GAME-ON/	2,990	5	1.49 (0.75, 2.96)	0.25	1.66 (0.73, 3.78)	0.23	1.69 (0.65, 4.42)	0.35	1.25 (0.03, 55.80)	0.91
	Oropharyngeal cancer	GLGC	2,641	5	0.90 (0.43, 1.85)	0.77	1.01 (0.43, 2.34)	0.99	1.08 (0.44, 2.64)	0.88	0.77 (0.01, 45.07)	0.91
		GAME-ON/ GLGC			(2)							
NPC1L1	Oral/ Oropharyngeal cancer	GAME-ON/	6,034	5	1.01 (0.38, 2.69)	0.99	0.90 (0.29, 2.82)	0.86	0.86 (0.24, 3.08)	0.83	0.22 (0.00, 102.42)	0.66
Nr CILI	Oral cancer	GLGC	2,990	5	1.02 (0.30, 3.41)	0.98	1.20 (0.29, 5.05)	0.80	1.29 (0.22, 7.41)	0.79	0.09 (0.00, 160.66)	0.57
		GAME-ON/ GLGC							, , ,			
	Oropharyngeal cancer	GAME-ON/	2,641	5	0.60 (0.16, 2.25)	0.45	0.60 (0.12, 3.04)	0.53	0.60 (0.10, 3.73)	0.62	0.20 (0.01, 688.64)	0.72
CETP	Oral/ Oropharyngeal cancer	GLGC	6,034	6	1.28 (0.64, 2.55)	0.49	1.24 (0.54, 2.81)	0.61	1.25 (0.43, 3.64)	0.71	0.82 (0.02, 27.60)	0.92
		GAME-ON/ GLGC										
	Oral cancer	GAME-ON/	2,990	6	1.65 (0.70, 3.88)	0.25	1.69 (0.61, 4.70)	0.31	1.63 (0.43, 5.87)	0.49	0.42 (0.01, 32.58)	0.72
	Oropharyngea cancer	GLGC	2,641	6	1.12 (0.45, 2.77)	0.81	1.05 (0.35, 3.20)	0.93	0.73 (0.17, 3.07)	0.69	1.50 (0.02, 142.22)	0.87

	GAME-ON/										
	GLGC			2 2 5 /4 2 4 2 2 2 2		0.04 (4.40.4.00)		2 4 2 (2 2 4 5 2 2)		4 00 (0 47 00 00)	
	Oral/ Oropharyngeal cancer	6,034	6	2.05 (1.24, 3.38)	0.01	2.21 (1.12, 4.08)	0.01	2.19 (0.81, 5.92)	0.18	1.83 (0.17, 20.00)	0.65
	GAME-ON/										
	GLGC										
PCSK9	Oral cancer	2,990	6	1.62 (0.89, 2.94)	0.11	1.80 (0.90, 3.62)	0.10	2.00 (0.73, 5.48)	0.23	2.17 (0.15, 32.13)	0.60
	GAME-ON/										
	GLGC				2.00						
	Oropharyngea cancer	2,641	6	3.49 (1.58, 7.68)	E-03	3.19 (1.40, 7.26)	0.01	2.73 (0.86, 8.70)	0.15	1.99 (0.04, 92.11)	0.74
	GAME-ON/										
	GLGC										
	Oral/ Oropharyngeal cancer	6,034	3	0.65 (0.42, 1.00)	0.05	0.71 (0.47, 1.08)	0.11	0.74 (0.47, 1.15)	0.31	0.90 (0.41, 1.95)	0.83
LDLR	GAME-ON/										
	GLGC										
	Oral cancer	2,990	3	0.53 (0.32, 0.87)	0.01	0.56 (0.32, 0.98)	0.04	0.57 (0.32, 1.04)	0.21	0.56 (0.18, 1.76)	0.50
	GAME-ON/										
	GLGC										
	Oropharyngeal cancer	2,641	3	0.90 (0.53, 1.52)	0.69	0.91 (0.55, 1.53)	0.73	1.08 (0.62, 1.89)	0.81	1.56 (0.64, 3.82)	0.51
400											

401 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, p-value.

OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent

404 to a 1 mmol/L decrease in LDL-C.

402

403

Stratification by cancer subsite in GAME-ON. When stratified by subsite, the adverse effect of PCSK9 appeared to be mainly in the oropharynx, (OR IVW 3.5; 95%CI 1.6, 7.7. $p = 2 \times 10^{-03}$), with limited evidence in the oral cavity (OR IVW 1.6; 0.9, 2.94, p = 0.11) (Table 2 & Fig 1). The effects appeared stronger in OPC versus OC, but with overlapping confidence intervals. LDLR was associated with a reduction in risk of OC (OR IVW 0.5; 95%CI 0.3, 0.9, p= 0.01), but there was little evidence of an association with OPC (OR IVW 0.9; 95%CI 0.5, 1.5, p = 0.69) (Table 2 and Fig 1). For both PCSK9 and LDLR associations, the direction of effect was generally consistent across the four MR methods tested (Table 2). Secondary analysis in GAME-ON. SNPs were also used to proxy circulating levels of LDL-C (77 SNPs), high-density lipoprotein cholesterol (HDL-C) (85 SNPs), total triglyceride (54 SNPs), total cholesterol (82 SNPs), apolipoprotein A (9 SNPs) and apolipoprotein B (14 SNPs) (S1 Table). There was limited evidence of an effect of any of these other lipid traits on either OC or OPC (Table 3 and S2 Fig).

Table 3. Mendelian randomization results of circulating lipid traits with risk of oral and

439 oropharyngeal cancer in GAME-ON

438

Target	N SNPs	Outcome	IVW OR (95% CI)	<i>P</i> -valu
LDL-C	77	Oral/ Oropharyngeal cancer	0.98 (0.87, 1.11)	0.79
		Oral cancer	0.99 (0.85, 1.15)	0.88
		Oropharyngeal cancer	1.03 (0.87, 1.21)	0.76
HDL-C	85	Oral/ Oropharyngeal cancer	0.98 (0.83, 1.16)	0.79
		Oral cancer	1.08 (0.88, 1.32)	0.45
		Oropharyngeal cancer	0.87 (0.71, 1.05)	0.15
Total triglycerides	54	Oral/ Oropharyngeal cancer	1.19 (1.01, 1.04)	0.04
		Oral cancer	1.19 (0.96, 1.46)	0.11
		Oropharyngeal cancer	1.19 (0.96, 1.47)	0.12
Total cholesterol	82	Oral/ Oropharyngeal cancer	1.04 (0.91, 1.18)	0.55
		Oral cancer	1.09 (0.93, 1.28)	0.30
		Oropharyngeal cancer	1.00 (0.84, 1.20)	0.96
Apolipoprotein A	9	Oral/ Oropharyngeal cancer	0.87 (0.73, 1.03)	0.11
		Oral cancer	0.90 (0.73, 1.12)	0.34
		Oropharyngeal cancer	0.82 (0.65, 1.04)	0.10
Apolipoprotein B	14	Oral/ Oropharyngeal cancer	1.04 (0.88, 1.22)	0.67
		Oral cancer	1.15 (0.89, 1.49)	0.29
		Oropharyngeal cancer	1.00 (0.83, 1.21)	0.98

441 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.

442 IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma

per SD increase in the circulating lipid trait (one SD for LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL,

Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total

445 cholesterol = 41.8 mg/dL).

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

Sensitivity analyses. IVW, MR Egger, weighted median, simple and weighted mode were carried out, in addition to IVW analysis accounting for LD structure (S2.1-2.5 Tables). The results adjusting for SNP correlation followed the same pattern as the main results (S3 Table). There was limited evidence of weak instrument bias being present (F-statistic >10) and the proportion of variance in the phenotype (R^2) explained by the genetic instruments ranged from 0.1 to 6% (S4 Table). In both primary and secondary analyses there was limited evidence of heterogeneity in the SNP effect estimates for IVW and MR Egger regression, except for in HDL-C (Q IVW 115.7, p= 0.01; Q MR Egger 115.6, p= 0.01) (S5 and S6 Tables). MR Egger intercepts also indicated limited evidence of directional pleiotropy (S7 and **S8 Tables**). For the primary analysis there were no clear outliers in both scatter and leaveone-out plots (Fig 3 and S3-6 Figs) and MR-PRESSO detected no individual outliers (S9 Table). Where there was evidence of violation of the NOME assumption for the HMGCR, NPC1L1 and CETP instruments (i.e. I² statistic <0.90) (**S10 Table**), MR-Egger was performed with SIMEX correction and effects were still consistent with the null (S11 Table). Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on combined oral/oropharyngeal cancer in GAME-ON. Replication in UK Biobank and meta-analysis of results. Primary MR analyses as described above were replicated in UK Biobank, showing limited evidence of an effect of geneticallyproxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR on risk of OC and OPC (S12 Table). Following IVW fixed-effects meta-analysis of GAME-ON and UK Biobank MR results, there was a consistently strong effect of genetically-proxied PSCK9 inhibition on combined

OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with good concordance between studies (I^2 = 22%) and methods used (**Fig 4** and **S7 Fig**). Effects for PCSK9 appeared stronger in relation to OPC (OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR IVW 1.4; 95%CI 0.8, 2.4), but with moderate heterogeneity between studies (I^2 = 41%) (**Fig 4**). Conversely, the protective effect for LDLR on OC and OPC combined was also consistent in the meta-analysis (OR IVW 0.7; 95%CI 0.5, 1.0), with good concordance between studies (I^2 = 0%) (**Fig 5** and **S7 Fig**). However, the protective effect seen specifically in relation to OC in GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9) was not replicated in UK Biobank (OR IVW 1.6; 95%CI 0.5, 4.8), with strong evidence of heterogeneity between the studies (I^2 = 66%).

Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterollowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites.

Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites.

Discussion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This included the absence of a protective effect of genetically-proxied inhibition of HMGCR, suggesting previous observational studies investigating the relationship between statins and head and neck cancer risk may be subject to residual confounding or bias. However, we did observe an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar magnitude to the protective effect seen in relation to cardiovascular disease using the same

genetic instrument (**Fig 2**). This PCSK9 effect was evident in both the GAME-ON (n=6,034 OC and OPC cases and n=6,585 controls) and UK Biobank datasets (n=839 OC and OPC cases and n=372,016 controls). We also found some evidence for a protective effect of cholesterol-lowering variants in *LDLR* on OC and OPC risk in both studies. The IVW analysis for HMGCR, NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure ($r^2 < 0.2$) followed the same pattern as the main results (**S3 Table**).

Association between PCSK9, LDLR and cancer risk. Despite the lack of consistent evidence for a role of cholesterol-lowering on risk of OC or OPC in this study, individual effects of both PCSK9 and LDLR were demonstrated which may implicate a role for these drug targets in the development of OC or OPC via other mechanisms. The effects identified in the present study are directionally consistent with a recent MR analysis of 1,615 combined head and neck cancer cases from UK Biobank, which also found that a 1 SD unit increase in LDL-C proxied by PCSK9 and LDLR was associated with a reduction (OR 0.7 95%Cl 0.4, 1.4, p= 0.35) and increase in odds (OR 1.6 95%Cl 1.0, 2.4, p= 0.05) of head and neck cancer, respectively [29]. The opposing effects of PCSK9 and LDLR in this study also suggests that cholesterol lowering is unlikely to be the main mechanism of action. However, this previous analysis is limited by the relatively small number of cases and heterogeneity of head and neck cancer subtypes, with no selection for the histological subtype of squamous cell carcinoma. In the present study, we focused specifically on oral and oropharyngeal subtypes of HNSCC.

Beyond the established role of *PCSK9* in cholesterol homeostasis, other potential pleiotropic effects are not well understood. Variants in *PCSK9* have been associated with an increased risk of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

LDL-C) [28]. However, a recent phenome-wide association study (PheWAS) did not find *PCSK9* or *LDLR* to be correlated with any non-lipid-related phenotypes, including diabetes [54]. There is limited *in vivo* and *in vitro* evidence that *PCSK9* might be involved in both cell proliferation and apoptosis. The gene was initially designated as NARC1 (neural apoptosis-regulated convertase 1), involved in apoptosis of cerebellar neurons [55] and *PCSK9* has since been found to be upregulated in some cancers [56, 57].

One suggested mechanism for a link with cancer progression is that the increased expression PCSK9 prevents LDL-receptor (LDLR) recycling, leading hypercholesterolaemia and more exogenous lipid to support the proliferation of the tumour [55]. Our study suggests the opposite, that genetically-proxied inhibition of PCSK9 results in an increased risk of OC or OPC. We hypothesise that access to intracellular LDL-C could in fact be pro-tumourigenic, providing a favourable environment for a developing tumour cell, maintaining membrane integrity and promoting cell division. Therapies such as statins, ezetimibe, and PCSK9 inhibitors may all lower LDL-C level through the upregulation of LDLreceptors, resulting in elevated intracellular cholesterol. However, cancer mechanisms are often context dependent and perhaps only the expression of PCSK9 and LDLR is relevant in head and neck cancer. CETP inhibitors instead block the transfer of cholesteryl ester from HDL-C to LDL-C, thereby raising HDL-C and lowering LDL-C (and apolipoprotein B), as well as enhancing reverse cholesterol transport [58]. Unlike statins, CETP inhibitors do not appear to increase the risk of type 2 diabetes, thought to be as a result of pancreatic islet cell cholesterol accumulation with use of other cholesterol-lowering drugs [59]. Therefore, the absence of effect when proxying CETP inhibition in this study, supports the possible mechanism of LDL-C uptake via the LDL-receptor in OC or OPC.

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

While both PCSK9 [60] and LDLR [61] are expressed in head and neck tumours, this was not evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not available in expression datasets [62]. Recent studies have associated elevated PCSK9 with alcohol use disorder, including the interesting possibility of using anti-PSCK9 monoclonal antibodies for the treatment of alcoholic liver disease [63, 64]. Given that alcohol is a wellknown risk factor for HNSCC, this pleiotropy could have partially explained the effect seen in our study, however we proxied the inhibition of PCSK9 and so would have expected to see a protective effect of this gene in HNSCC cases who may have been heavy alcohol drinkers. Further investigation is required to untangle the relationship between PCSK9, alcohol and head and neck cancer. Comparison with previous studies. It is believed that statins could play a potential role in cancer chemoprevention which may reduce the risk of some site-specific cancers such as prostate [65] and ovarian [30], but not all. Some of these studies have reported cancer risk reductions by as much as 50 - 65% [66-68]. However, meta-analyses and clinical trials have contradicted these findings [69, 70]. In addition to confounding, immortal time bias likely inflated observational results because, to be classified as a long-term statin user necessitates that users survived without cancer over a long period [19, 71]. Dickerman et al. used electronic records from 733,804 adults with 10-year follow-up to emulate a trial design. To achieve this a pre-specified protocol was set, including eligibility criteria and checks were made to ensure effect estimates for statins on cancer were comparable

between the large observational dataset and trial. The authors found little indication that

statin therapy influences cancer incidence, which was consistent with the analyses of

randomised trials (with a 10-year cancer-free survival difference of -0.3% 95%CI -1.5%, 0.5%) [19]. Nonetheless, recent MR studies [29, 30] have identified an association between variants in *HMGCR* with cancer risk, but not alternative cholesterol-lowering treatments or genetically-predicted LDL-C, suggesting that statins may reduce cancer risk through a cholesterol independent pathway. A recent case-control study of over 11,000 participants found an inverse association between statin use and the occurrence of HNSCC (OR 0.86, 95%CI 0.77, 0.95, p= <0.01, of prior statin exposure for cases compared to propensity score-matched controls) [18]. However, a wider systematic review found that the evidence for the role of statins in the prevention of HNSCC was limited [72]. As HNSCC incidence is a rare outcome, randomised controls trials are not feasible, so we must be cautious interpreting the available observational findings given the potential for bias and confounding as discussed previously.

In contrast to previous MR studies assessing overall cancer risk [29] and ovarian specific risk [30], the MR carried out here in relation to OC and OPC showed no effect using genetic instruments for HMGCR (statins). There was also limited evidence for a causal effect of NPC1L1 (ezetimibe), CETP (CETP inhibitors) as well as a number of other circulating lipid traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with PCSK9 and LDLR are via LDL-C lowering or another less well-established pathway [73, 74], such as receptor regulation for viral entry, synthesis of sex hormones and resultant dysregulated metabolism [75-77].

Strengths and limitations of this study. Protective associations between cholesterol-lowering therapies such as statins and head and neck cancer risk seen in previous

observational studies could be a result of reverse causation, immortal time bias, lack of randomisation or confounding by socioeconomic status, smoking or HPV infection, for example. Our study applied MR in an attempt to overcome these issues, using the largest number of SNPs identified from the latest GWAS for both cholesterol-lowering and head and neck cancer that could be identified in the literature [25, 34]. A series of pleiotropyrobust MR methods and outlier detection were applied to rigorously explore the possibility that findings were not biased as a result of pleiotropy. However, there was no HPV data available in these summary results to enable more detailed stratified analysis of OPC. We did replicate findings for PCSK9 and LDLR, but the number of cases are low. Finally, most participants in the GAME-ON network [34] were of European or North American decent, with only around 11% from South America, and participants included in the UK Biobank analysis were exclusively of European descent, so more work is required to determine if our results translate to other ancestry groups.

In conclusion, our MR analyses provided little evidence for a role of cholesterol lowering in OC or OPC risk although effects of genetically-proxied inhibition of *PCSK9* and cholesterol-lowering variants in *LDLR* were observed in relation to OPC and OC risk. Given the lack of a common pathway to carcinogenesis in OC or OPC, metabolic targets that may be common to all tumours, regardless of the activated molecular pathway, could help simplify a preventative or therapeutic approach [78]. Replication of our findings in other head and neck cancer datasets and use of individual-level follow-up data with HPV status could provide further insight into the effect of these genetic instruments on risk, treatment outcomes and survival in head and neck cancer. With more evidence, future randomised

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

control trials could focus on treating high risk OC or OPC groups, such as those with severe dysplasia or who are HPV-16 E6 positive, with cholesterol-lowering therapies. Data availability statement Summary-level analysis was conducted using publicly available GWAS data [25, 33]. Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1) [34]. Access to UK Biobank (https://www.ukbiobank.ac.uk/) data is available to researchers through application. Code availability statement Two-sample MR analyses were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code used in this analysis will be made available at: https://github.com/rcrichmond/cholesterol_lowering_headandneckcancer **Acknowledgements** M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

any Author Accepted Manuscript version arising from this submission. UK Biobank approval was given for this project (ID 40644 "Investigating aetiology, associations and causality in diseases of the head and neck") and UK Biobank GWAS data was also accessed under the application (ID 15825 "MR-Base: an online resource for Mendelian randomization using summary data" - Dr. Philip Haycock). R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). R.M.M. was supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) and is part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC UU 12013/1, MC UU 12013/2, and MC UU 12013/3) and the University of Bristol. JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). R.M.M. and A.R.N. are supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. This publication presents data from the Head and Neck 5000 study. The study was a component of independent research funded by the NIHR under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol Research Capability Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant number: C18281/A19169). B.D. and the University of Pittsburgh head and neck cancer case-control study are supported by US National Institutes of Health (NIH) grants: P50 CA097190, P30 CA047904 and R01 DE025712. The genotyping of the HNSCC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). The University of North Caroline (UNC) CHANCE study was supported in part by the National Cancer Institute (R01-CA90731). E.E.V and D.L are supported by Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). E.H.T and P.S. were supported by the GENCAPO/FAPESP grant (10/51168-0).

Competing Interests

The authors declare no conflicts of interest. The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors alone are responsible for the views expressed in this article.

References

- 681 1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral 682 Oncol. 2009;45(4-5):309-16. 683 2. Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender 684 and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral 685 tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-686 based analysis. Oncology. 2011;81(1):12-20. 687 3. Cancer Research UK (CRUK). Head and neck cancer statistics 2019 [cited 2019 688 11/04/2019]. Available from: https://www.cancerresearchuk.org/health-689 professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-690 Two. 691 4. Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom 692 National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S181-S90. 693 5. De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and 694 psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol 695 Head Neck Surg. 1999;120(3):427-36. 696 6. Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck 697 squamous cell cancer: A tale of three cancers? Clin Otolaryngol. 2018;43(4):999-1003. 698 7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human
- papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.
 2010;363(1):24-35.

- 701 8. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal
- cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-
- 703 309.
- 704 9. Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO. Drug repurposing in
- 705 cancer. Pharmacol Res. 2017;124:74-91.
- 706 10. Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf.
- 707 2012;3(3):133-44.
- 708 11. Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The
- 709 'top 100' drugs and classes in England: an updated 'starter formulary' for trainee
- 710 prescribers. British Journal of Clinical Pharmacology. 2018;84(11):2562-71.
- 711 12. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA
- 712 reductase. Science. 2001;292(5519):1160-4.
- 713 13. Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al.
- 714 Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein
- 715 Levels and Cardiovascular Risk. JAMA. 2017;318(10):947-56.
- 716 14. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and Reduced Cancer-Related
- 717 Mortality. New Engl J Med. 2012;367(19):1792-802.
- 718 15. Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer BA, et al.
- 719 Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting
- monocarboxylate transporters. Sci Rep. 2018;8(1):16804.

- 721 16. Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum
- 722 lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol. 2011;32(1):34-7.
- 723 17. Mehta R, Gurudath S, Dayansoor S, Pai A, Ganapathy KS. Serum lipid profile in
- 724 patients with oral cancer and oral precancerous conditions. Dent Res J (Isfahan).
- 725 2014;11(3):345-50.
- 726 18. Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and
- 727 head and neck cancer: Population-based case-control study in Han population. Head Neck-J
- 728 Sci Spec. 2019;41(5):1193-8.
- 729 19. Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws
- in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-
- 731 6.
- 732 20. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
- 733 contribute to understanding environmental determinants of disease? Int J Epidemiol.
- 734 2003;32(1):1-22.
- 735 21. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
- 736 inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.
- 737 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
- guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
- 739 23. Walker VM, Smith GD, Davies NM, Martin RM. Mendelian randomization: a novel
- 740 approach for the prediction of adverse drug events and drug repurposing opportunities. Int J
- 741 Epidemiol. 2017;46(6):2078-89.

- 742 24. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.
- 743 Biological, clinical and population relevance of 95 loci for blood lipids. Nature.
- 744 2010;466(7307):707-13.
- 745 25. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.
- Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-+.
- 747 26. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-
- 748 density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,
- 749 epidemiologic, and clinical studies. A consensus statement from the European
- 750 Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.
- 751 27. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random
- allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease
- 753 mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian
- 754 randomization study. J Am Coll Cardiol. 2015;65(15):1552-61.
- 755 28. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al.
- 756 Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J
- 757 Med. 2016;375(22):2144-53.
- 758 29. Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the
- 759 effect of statins on cancer risk using genetic variants: a Mendelian randomization study in
- 760 UK Biobank. medRxiv. 2020:2020.02.28.20028902.

- 761 30. Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association
- 762 Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian
- 763 Cancer. JAMA. 2020;323(7):646-55.
- 764 31. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-
- 765 specific haplotype structure and linking correlated alleles of possible functional variants.
- 766 Bioinformatics. 2015;31(21):3555-7.
- 767 32. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian
- 768 Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033-
- 769 42.
- 770 33. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide
- study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
- 772 Nat Commun. 2016;7:11122.
- 773 34. Lesseur C, Diergaarde B, Olshan AF, Wunsch V, Ness AR, Liu G, et al. Genome-wide
- association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.
- 775 Nat Genet. 2016;48(12):1544-50.
- 776 35. Consortium O. Consortium launches genotyping effort. Cancer Discov.
- 777 2013;3(12):1321-2.
- 778 36. Dudding T, Johansson M, Thomas SJ, Brennan P, Martin RM, Timpson NJ. Assessing
- the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal
- 780 cancer using Mendelian randomization. Int J Cancer. 2018;143(5):1029-36.

- 781 37. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian
- randomization studies. Int J Epidemiol. 2013;42(5):1497-501.
- 783 38. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing
- 784 Mendelian randomization analyses using summarized data. Int J Epidemiol.
- 785 2017;46(6):1734-9.
- 786 39. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data
- 787 in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur
- 788 J Epidemiol. 2015;30(7):543-52.
- 789 40. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
- 790 instrumental variables in Mendelian randomization: comparison of allele score and
- 791 summarized data methods. Stat Med. 2016;35(11):1880-906.
- 792 41. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive
- 793 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
- 794 Nat Genet. 2015;47(10):1121-30.
- 795 42. Hemani G, Bowden J, Smith GD. Evaluating the potential role of pleiotropy in
- 796 Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-R208.
- 797 43. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
- 798 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.
- 799 2015;44(2):512-25.

800 44. Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian 801 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet 802 Epidemiol. 2016;40(4):304-14. 803 45. Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian 804 randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-805 98. 806 46. Bowden J, Del Greco MF, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing 807 the suitability of summary data for two-sample Mendelian randomization analyses using 808 MR-Egger regression: the role of the I-2 statistic. Int J Epidemiol. 2016;45(6):1961-74. 809 47. Bowden J, Spiller W, Del Greco F, Sheehan N, Thompson J, Minelli C, et al. Improving 810 the visualization, interpretation and analysis of two-sample summary data Mendelian 811 randomization via the Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264-78. 812 48. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread 813 horizontal pleiotropy in causal relationships inferred from Mendelian randomization 814 between complex traits and diseases. Nat Genet. 2018;50(8):1196. 815 49. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide 816 genetic data on ~500,000 UK Biobank participants. bioRxiv. 2017:166298. 817 50. Mitchell R, Hemani, G, Dudding, T, Corbin, L, Harrison, S, Paternoster, L. UK Biobank 818 Genetic Data: MRC-IEU Quality Control, version 2.

https://doi.org/10.5523/bris.1ovaau5sxunp2cv8rcy88688v. 2019.

819

- 820 51. Mitchell R, Elsworth BL, Mitchell R, Raistrick CA, Paternoster L, Hemani G, Gaunt TR
- MRC IEU UK Biobank GWAS pipeline version 2.
- https://doi.org/10.5523/bris.pnoat8cxo0u52p6ynfaekeigi. 2019.
- 823 52. Schwarzer G. meta: an R package for metaanalysis. R News. 2007;7:40-5.
- Higgins SG. Measuring inconsistency in metaanalyses. BMJ Br Med J. 2003;327:557-
- 825 60.
- 826 54. Safarova MS, Satterfield BA, Fan X, Austin EE, Ye Z, Bastarache L, et al. A phenome-
- wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. NPJ Genom
- 828 Med. 2019;4:3.
- 829 55. Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 biology
- beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52-62.
- Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, et al. Network
- analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol.
- 833 2017;13(8):938.
- 834 57. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar
- NR, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome.
- 836 Proteomics Clin Appl. 2013;7(5-6):355-66.
- 837 58. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL
- 838 receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent
- 839 mechanism. Atherosclerosis. 2014;235(2):449-62.

- 840 59. Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis.
- 841 2018;278:143-6.
- 842 60. The Human Protein Atlas. PCKS9 2020 [Available from:
- https://www.proteinatlas.org/ENSG00000169174-PCSK9/pathology.
- 844 61. The Human Protein Atlas. LDLR 2020 [Available from:
- https://www.proteinatlas.org/ENSG00000130164-LDLR/pathology.
- 846 62. The Human Protein Atlas. LDLR Tissue 2020 [Available from:
- https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue.
- 848 63. Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9
- inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports.
- 850 2019;9(1):17167.
- 851 64. Lee JS, Rosoff D, Luo A, Longley M, Phillips M, Charlet K, et al. PCSK9 is Increased in
- 852 Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. Alcoholism: Clinical and
- 853 Experimental Research. 2019;43(6):1163-9.
- 854 65. Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason
- score-specific prostate cancer: A hospital-based cohort study. Cancer Medicine.
- 856 2019;8(17):7399-407.
- 857 66. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and
- the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-92.
- 859 67. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer
- in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-8.

- 861 68. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins
- and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162(4):318-25.
- 863 69. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C,
- 864 Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of
- 865 individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One.
- 866 2012;7(1):e29849.
- 867 70. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a
- 868 meta-analysis. JAMA. 2006;295(1):74-80.
- 869 71. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial
- prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin
- 871 Epidemiol. 2016;79:70-5.
- 872 72. Saka Herran C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J. Protective effects of
- 873 metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic
- 874 review. Oral Oncol. 2018;85:68-81.
- 73. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray
- and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
- 877 Neoplasia. 2002;4(4):337-46.
- 878 74. Osmak M. Statins and cancer: current and future prospects. Cancer Lett.
- 879 2012;324(1):1-12.
- 880 75. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and
- 881 Cancer-Related Mortality. Physiol Rev. 2015;95(3):727-48.

882 76. Joost HG. Diabetes and cancer: Epidemiology and potential mechanisms. Diabetes

883 Vasc Dis Re. 2014;11(6):390-4.

884

885

888

889

890

891

892

893

894

895

77. Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried


W, et al. Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. Cancer

886 Prev Res. 2012;5(11):1260-72.


887 78. Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9

expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.

Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* variants on the oral and oropharyngeal cancer subsites in GAME-ON.




905
906
907
908
909
910
911
912 Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR* single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on combined oral/oropharyngeal cancer in GAME-ON.





Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites .






Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering

LDLR single nucleotide polymorphisms on head and neck cancer subsites

